Bioplastics producer Metabolix has survived the termination of its joint venture with DSM but is struggling to develop new sources of revenue. A shrinking cash reserve and the need to acquire financing for a new commercial-scale facility before substantial revenue growth can be achieved make a further decline in the company’s share price likely.
Only speculative investors with a high tolerance for risk should consider buying this company’s shares.
Tags: price, investing, risk-tolerant investors
Source: Seeking Alpha, 2013-09-20.